Skip to main content
CVE:VIR

Viridium Pacific Group Competitors

C$0.38
+0.02 (+5.56 %)
(As of 06/7/2019)
Add
Compare
Today's Range
C$0.37
C$0.41
50-Day Range
C$0.38
C$0.38
52-Week Range
C$0.36
C$1.15
Volume26,500 shs
Average Volume92,632 shs
Market CapitalizationC$37.52 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Viridium Pacific Group (CVE:VIR) Vs. EPI, WMD, NINE, FLWR, ASP, and RX

Should you be buying VIR stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Viridium Pacific Group, including ESSA Pharma (EPI), WeedMD (WMD), Delta 9 Cannabis (NINE), The Flowr (FLWR), Acerus Pharmaceuticals (ASP), and BioSyent (RX).

Viridium Pacific Group (CVE:VIR) and ESSA Pharma (CVE:EPI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Viridium Pacific Group and ESSA Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viridium Pacific Group0000N/A
ESSA Pharma0000N/A

Earnings and Valuation

This table compares Viridium Pacific Group and ESSA Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridium Pacific GroupC$1.09 million34.46C$-12,637,824.00C($0.13)-2.97
ESSA PharmaN/AN/AN/AC($0.99)-8.27

ESSA Pharma has lower revenue, but higher earnings than Viridium Pacific Group. ESSA Pharma is trading at a lower price-to-earnings ratio than Viridium Pacific Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Viridium Pacific Group and ESSA Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viridium Pacific GroupN/AN/AN/A
ESSA PharmaN/AN/AN/A

Summary

Viridium Pacific Group beats ESSA Pharma on 3 of the 3 factors compared between the two stocks.

Viridium Pacific Group (CVE:VIR) and WeedMD (CVE:WMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Viridium Pacific Group and WeedMD, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viridium Pacific Group0000N/A
WeedMD02002.00

WeedMD has a consensus price target of C$0.58, indicating a potential upside of 112.12%. Given WeedMD's higher possible upside, analysts plainly believe WeedMD is more favorable than Viridium Pacific Group.

Earnings and Valuation

This table compares Viridium Pacific Group and WeedMD's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridium Pacific GroupC$1.09 million34.46C$-12,637,824.00C($0.13)-2.97
WeedMDC$27.21 million2.49C$-21,702,912.00C($0.09)-3.13

Viridium Pacific Group has higher earnings, but lower revenue than WeedMD. WeedMD is trading at a lower price-to-earnings ratio than Viridium Pacific Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Viridium Pacific Group and WeedMD's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viridium Pacific GroupN/AN/AN/A
WeedMDN/AN/AN/A

Viridium Pacific Group (CVE:VIR) and Delta 9 Cannabis (CVE:NINE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Viridium Pacific Group and Delta 9 Cannabis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viridium Pacific Group0000N/A
Delta 9 Cannabis0000N/A

Earnings and Valuation

This table compares Viridium Pacific Group and Delta 9 Cannabis' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridium Pacific GroupC$1.09 million34.46C$-12,637,824.00C($0.13)-2.97
Delta 9 CannabisC$12.87 million6.94C$4.69 millionC$0.0519.07

Delta 9 Cannabis has higher revenue and earnings than Viridium Pacific Group. Viridium Pacific Group is trading at a lower price-to-earnings ratio than Delta 9 Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Viridium Pacific Group and Delta 9 Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viridium Pacific GroupN/AN/AN/A
Delta 9 CannabisN/AN/AN/A

Summary

Delta 9 Cannabis beats Viridium Pacific Group on 4 of the 5 factors compared between the two stocks.

Viridium Pacific Group (CVE:VIR) and The Flowr (CVE:FLWR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Viridium Pacific Group and The Flowr, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viridium Pacific Group0000N/A
The Flowr0000N/A

The Flowr has a consensus price target of C$0.88, indicating a potential upside of 260.54%. Given The Flowr's higher possible upside, analysts plainly believe The Flowr is more favorable than Viridium Pacific Group.

Earnings and Valuation

This table compares Viridium Pacific Group and The Flowr's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridium Pacific GroupC$1.09 million34.46C$-12,637,824.00C($0.13)-2.97
The FlowrC$7.51 million11.80C$-343,678,650.00C($0.95)-0.26

Viridium Pacific Group has higher earnings, but lower revenue than The Flowr. Viridium Pacific Group is trading at a lower price-to-earnings ratio than The Flowr, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Viridium Pacific Group and The Flowr's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viridium Pacific GroupN/AN/AN/A
The FlowrN/AN/AN/A

Viridium Pacific Group (CVE:VIR) and Acerus Pharmaceuticals (TSE:ASP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Viridium Pacific Group and Acerus Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viridium Pacific Group0000N/A
Acerus Pharmaceuticals0000N/A

Earnings and Valuation

This table compares Viridium Pacific Group and Acerus Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridium Pacific GroupC$1.09 million34.46C$-12,637,824.00C($0.13)-2.97
Acerus PharmaceuticalsC$1.09 million63.77C$-55,353,168.00C($0.04)-1.25

Viridium Pacific Group has higher revenue and earnings than Acerus Pharmaceuticals. Viridium Pacific Group is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Viridium Pacific Group and Acerus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viridium Pacific GroupN/AN/AN/A
Acerus PharmaceuticalsN/AN/AN/A

Summary

Acerus Pharmaceuticals beats Viridium Pacific Group on 3 of the 5 factors compared between the two stocks.

Viridium Pacific Group (CVE:VIR) and BioSyent (CVE:RX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Viridium Pacific Group and BioSyent, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viridium Pacific Group0000N/A
BioSyent02002.00

BioSyent has a consensus price target of C$7.00, indicating a potential downside of 7.65%. Given BioSyent's higher possible upside, analysts plainly believe BioSyent is more favorable than Viridium Pacific Group.

Earnings and Valuation

This table compares Viridium Pacific Group and BioSyent's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridium Pacific GroupC$1.09 million34.46C$-12,637,824.00C($0.13)-2.97
BioSyentC$22.33 million4.31C$3.68 millionC$0.2926.14

BioSyent has higher revenue and earnings than Viridium Pacific Group. Viridium Pacific Group is trading at a lower price-to-earnings ratio than BioSyent, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Viridium Pacific Group and BioSyent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viridium Pacific GroupN/AN/AN/A
BioSyentN/AN/AN/A

Summary

BioSyent beats Viridium Pacific Group on 5 of the 6 factors compared between the two stocks.


Viridium Pacific Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
EPI
ESSA Pharma
0.6$8.20+6.7%C$145.78 millionN/A-8.27
WMD
WeedMD
1.3$0.28+3.6%C$95.35 millionC$27.21 million-3.13
NINE
Delta 9 Cannabis
1.1$1.03+2.9%C$89.36 millionC$12.87 million19.07Gap Up
FLWR
The Flowr
1.0$0.25+2.0%C$70.01 millionC$7.51 million-0.26Gap Up
Acerus Pharmaceuticals logo
ASP
Acerus Pharmaceuticals
0.5$0.05+22.2%C$69.19 millionC$1.09 million-1.25News Coverage
Gap Down
RX
BioSyent
0.8$7.58+0.3%C$64.81 millionC$22.33 million26.14
Cipher Pharmaceuticals logo
CPH
Cipher Pharmaceuticals
0.7$1.41+13.5%C$43.16 millionC$21.61 million7.01News Coverage
Gap Down
MDP
Medexus Pharmaceuticals
0.6$7.12+1.7%C$38.66 millionC$108.29 million-3.93
ZOM
Zomedica Pharmaceuticals Corp. (ZOM.V)
0.6$0.29+7.0%C$36.73 millionN/A-2.61Gap Down
IN
InMed Pharmaceuticals
0.6$4.19+1.7%C$33.73 millionN/A-2.40
NDVA
Indiva
1.3$0.43+3.5%C$27.54 millionC$7.92 million-3.32
Harvest One Cannabis logo
HVT
Harvest One Cannabis
0.4$0.09+0.0%C$21.51 millionC$8.50 million-0.24News Coverage
EVE
Eve & Co Incorporated
1.0$0.26+0.0%C$21.32 millionC$2.84 million-0.80News Coverage
SUGR
SugarBud Craft Growers
0.7$0.05+0.0%C$11.81 millionC$66,906.00-0.03
NU
NeutriSci International
0.5$0.17+8.8%C$8.65 millionC$74,572.00-12.14
AQS
Aequus Pharmaceuticals
0.9$0.15+0.0%C$6.03 millionC$2.59 million-13.64
LBL
Lattice Biologics
0.5$0.04+0.0%C$4.67 millionC$2.24 million-2.22
THCX
(THCX.V)
0.6$5.30+6.2%C$0.00N/A0.00High Trading Volume
News Coverage
GLH
31444
0.4N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
ACG
438280
0.6N/AN/AC$0.00N/A0.00Gap Up
HC
815446
0.5N/AN/A$0.00N/A0.00Gap Up
BIO
Bio-Rad Laboratories
0.5N/AN/A$0.00N/A0.00High Trading Volume
BBM
Blueberries Medical
0.6N/AN/A$0.00N/A0.00High Trading Volume
LOVE
Cannara Biotech
0.7N/AN/A$0.00N/A0.00High Trading Volume
CALI
China Auto Logistics
1.3N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
MJ
ETFMG Alternative Harvest ETF
0.5N/AN/A$0.00N/A0.00News Coverage
Gap Up
BOSS
Global X Founder-Run Companies ETF
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
LHS
Liberty Health Sciences
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
LIB
Liberty Leaf
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
Gap Up
MMEN
Medmen Enterprises
0.6N/AN/A$0.00N/A0.00High Trading Volume
RQB
Ravenquest Biomed
0.6N/AN/A$0.00N/A0.00High Trading Volume
TGIF
SoFi Weekly Income ETF
0.6N/AN/A$0.00N/A0.00High Trading Volume
Valeant Pharmaceuticals International logo
VRX
Valeant Pharmaceuticals International
0.5N/AN/AC$0.00N/A0.00
VRT
Vertiv
0.5N/AN/A$0.00N/A0.00News Coverage
Gap Up
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.